GET DAILY SIGNALSStarling Oncology (STLN): Can Shares Recover to the $9 Analyst Target?
Key Takeaways
- The central $9 price target is the arithmetic mean of four verified analyst price targets, which range from $8 to $10.
- At the latest close of about $3.62, reaching $9 implies upside of roughly 149% — a very large move requiring a full recovery and then new highs.
- All four analysts rate the stock a Buy, giving it a Strong Buy consensus, but targets were trimmed after the Q3 2026 report.
- The strongest support is the company's expanding capitated (fixed per-member) revenue model and its 2027 capitation growth outlook.
- The biggest risks are a Q3 earnings miss, narrowed full-year guidance, continued losses, and concerns over the capitated-revenue trajectory.
- For more on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven strategies tracking names like STLN.
Analyst Price Targets and Consensus View
The $9 central target reflects a small, uniformly bullish analyst base. Four firms with current, attributable targets were reviewed: B. Riley Securities lowered its target to $10 from $11 (Buy) on November 6, 2026; Lake Street cut its target to $8 from $10 (Buy) the same day; Needham reiterated a $9 target (Buy) on October 14, 2026; and BTIG held a $9 target (Buy). The arithmetic mean of $10, $8, $9 and $9 is $9.00, with an approximate low-to-high range of $8 to $10. I also checked this using Tickeron’s AI Screener to see how STLN compares to others in the industry.
These figures are notably above pre-earnings consensus estimates from some aggregators, which had shown a higher average before the post-Q3 target cuts. The revisions followed a disappointing third-quarter report, in which EPS missed expectations even as revenue beat. Analysts remain constructive, but the downward drift in targets signals reduced confidence in the near-term trajectory.
Current Market Position and Path Toward the Target
Shares closed at $3.62 on November 6, 2026, down about 46% in a single session after the November 5 earnings release, before a partial pre-market rebound. Reaching $9 from $3.62 requires a gain of roughly 149%, a very large move by any standard. The target also sits above the stock's 52-week high of $7.13, meaning the path would require the shares to recover their losses and then break into record territory.
Such a move would likely depend on a sustained re-rating of the company's value-based oncology and specialty pharmacy business. With trailing-twelve-month revenue near $620 million and a market capitalization around $369 million, the stock trades at a modest price-to-sales multiple, yet the company is still unprofitable on a net basis.
What Could Support a Move Toward the Target
The core bull case is the company's shift toward capitated, delegated-risk contracts, in which it receives fixed per-member payments for managing cancer care. Management has guided for capitated revenue to reach about $300 million in 2027, a trajectory analysts have called "thesis-changing." The Starling Nexus portal, which centralizes utilization management and prior authorization across the affiliated network, is seen as a growth and margin lever. From what I see, continued execution on out-of-Florida expansion and specialty-pharmacy margins could support a re-rating toward the analyst range.
What Could Prevent the Target From Being Reached
The immediate obstacle is earnings quality. Third-quarter EPS of ($0.13) missed the ($0.05) consensus by eight cents, and management narrowed full-year 2026 revenue guidance to $650–$660 million from $650–$670 million, below the roughly $665 million consensus. Lake Street noted investors "disliked the company's updated capitated revenue" commentary. Structurally, the company remains unprofitable, carries a negative book value, and holds about $103 million in total debt against roughly $37 million in cash. Dilution is a live concern, with shares outstanding up nearly 20% year over year.
Technical Levels and Market Structure
The stock's 52-week range spans roughly $2.32 to $7.13. The recent collapse took shares below both the 50-day moving average near $6.43 and the 200-day moving average near $4.76, leaving the price in deeply oversold territory with an RSI near 25. Short interest is about 6.4% of the float, which could fuel sharp rallies on positive news but also adds to downside volatility. The $7.13 prior high stands as a major psychological and technical resistance zone that any move toward $9 would have to clear decisively.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always disclose a uniform timeframe. For STLN, the most important items to watch are the next quarterly earnings report, updated capitated-revenue and 2027 guidance, progress on the Nexus platform and e-prescribing rollout, new delegated-risk contract announcements, and any analyst target revisions. Healthcare-policy developments affecting Medicare Advantage and Medicaid (including Medi-Cal) reimbursement are also directly relevant to the company's value-based model.
Final Assessment
The $9 target is the arithmetic mean of four Buy-rated analyst targets ranging from $8 to $10, and it implies roughly 149% upside from the latest close — a very large move that would require a full recovery from the post-earnings collapse plus new record highs. Support rests on capitated-revenue growth, the 2027 outlook, and a low revenue multiple. The principal obstacles are the Q3 EPS miss, narrowed guidance, persistent losses, dilution, and investor skepticism over the capitation trajectory. The analyst range itself signals uncertainty, with targets cut across the board after earnings. Investors should watch the next earnings report and capitation guidance rather than treat $9 as a forecast.
Exploring AI Daily Buy/Sell Signals
In my analysis of names like STLN, I rely on Tickeron's AI Daily Buy/Sell Signals to monitor shifting conditions. The tool uses artificial intelligence to generate Buy, Sell, or Hold signals from technical behavior and market data, which helps me stay efficient when tracking volatile stocks without manual scanning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STLN's RSI Indicator stays in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +11.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where STLN advanced for three days, in 258 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
STLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STLN as a result. In 65 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for STLN turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 35 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STLN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STLN crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-14.808) is normal, around the industry mean (204.532). P/E Ratio (-12.483) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.124) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. STLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement